Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks
|
|
- Duane Wilcox
- 6 years ago
- Views:
Transcription
1 Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks
2 About Sartorius Stedim BioOutsource Sartorius Stedim BioOutsource Ltd. is a leading provider of contract testing services to the global biopharmaceutical and biotechnology industry. Biosafety testing within the manufacturing process should be established in the early stages of drug development. We offer biosafety testing services throughout development and manufacture: ` ` Master Cell Bank (MCB) ` ` Working Cell Bank (WCB) ` ` End of Production Cell Bank (EPC) `Bulk ` Harvest `Genetic ` Stability ` ` Final Product and GMP Lot Release All of our biosafety testing is compliant with appropriate GMP, GLP and GCP quality standards. Further information on our range of services is available on our website: Contents Introduction to Safety Testing for CHO Cell Banks 2 Table 1 General Testing in Compliance with ICH Q5A 3 Master and End Of Production Cell Bank Testing 3 Table 2 MCB and EPC Testing 4 Working Cell Bank (WCB) Testing 5 Table 3 WCB Testing 5 Bulk Harvest (Unprocessed Bulk) Testing 5 Table 4 Unprocessed Bulk Harvest Testing 5 Purified Bulk Harvest and Final Product Testing 5 Table 5 Purified Bulk Harvest and Final Product Testing 6 Genetic Stability Testing 6 Table 6 Genetic Stability Testing 6 Further Possible Testing 6 2
3 Introduction to safety testing for CHO cell banks CHO cells are by far the most commonly used production cells in the biopharmaceutical industry. These cells are used for a number of reasons but one of them is the good safety record of no known incidence of patient infection with a contamination from a product manufactured on these cells. The guidelines for the safety testing of these products were globally harmonised in 2003 to allow a world-wide single panel of tests to assist drug developers to move through regulatory submissions. Since 2007, BioOutsource has performed biosafety testing of over 200 recombinant protein products from Chinese Hamster Ovary (CHO) cell banks. The general testing strategy outlined in this document complies with international regulatory guidelines and remains current owing to our on-going dialogue with worldwide regulatory authorities. 1 The guidelines outline a safety testing programme which is dependent on three aspects; testing of the starting materials which includes the cell banks, testing of the in-process materials which are typically the bulk harvest and the ultimate stage which is validation of the virus removal ability of the downstream purification process. The full profile of safety testing is developed over a number of years as the clinical trials are engaged and the product moves to commercialisation. BioOutsource scientists have a wealth of experience and knowledge and will advise on the most appropriate and cost-effective testing strategy to meet scientific and regulatory requirements. The package of testing recommended by our scientists take into consideration the history of the cell line, raw materials used during production, product dosage, therapeutic application, clinical stage, patient population, in addition to other factors which may impact the strategy. A general overview of testing requirements is described in this document. From the International Congress on Harmonisation in 2003 each regulatory jurisdiction prepared its own safety testing guideline which all have slightly different wording. Therefore the guidance for testing cell banks is described in European Medicines Agency and the United States Food and Drug Administration Guidance documents. Our scientists have devised a package of recommended safety testing and characterisation for CHO projects to ensure the ultimate safety of the final product which will satisfy both agencies. A general overview of tests required during production of a recombinant product is detailed below. Test MCB WCB EPC Bulk Harvest Final Product Identity Mycoplasma Sterility In vitro assays In vivo assays Antibody tests Retrovirus infectivity Reverse transcriptase Electron microscopy Species specific tests Residual DNA Table 1 General testing requirement in compliance with ICH Q5A Master and End of Production Cell Bank Testing Cells used in the production of biologic products are initially banked as a Master Cell Bank (MCB), which consists of a bank of fully characterised cells processed together to ensure uniformity and stability. Characterisation and testing of the MCB for bacterial and viral contaminants should be performed as described in International Conference on Harmonisation (ICH) Q5A prior to initiation of a Phase I clinical trial 1. In addition to testing for the presence of microbiological contaminants, extensive screening for the presence of both exogenous and endogenous viral contamination should be performed. 3
4 Testing for non-endogenous viruses should include in vitro and in vivo inoculation tests, and any other specific tests which are appropriate for detection of potential contaminating viruses, based on the passage history of the cell line. MCB testing is performed once and the testing package is repeated on the End of Production Cell Bank (EPC) in order to determine that the cells at the age of limit remain unchanged from the original cells, and to detect any low level contamination which may have been present but undetected in the MCB. Testing the EPC also allows detection of latent infections as well as any contaminants which may have introduced during the production process. Testing of EPC at the limit of cell age used in production should be performed prior to submitting a Product Licence Application (PLA). A summary of the testing required is described in Table 2. Please note the sample volumes listed in the tables below are a guide and may vary for specific projects. Please speak to our scientists, who can advise on the required sample volumes for each project. Description Microbiological contaminants Sterility test and qualification of sterility test by direct inoculation (Eu Pharm current edition sterility, US Pharmacopoeia <71>) (Technical Note T1) Test for mycoplasma including mycoplasmastasis assay (EP and USP <63> ) (Agar, broth and indicator cells) (Technical Note T1) Appearance SP-GSM SP-GSM Test 1% of cell bank (minimum 2 vials) plus 3X number tested for qualification Test 1 vial + 23 ml supernatant and 1 vial + 18 ml supernatant for mycoplasmastasis Morphology by light microscopy TSOP179 1 Live cells required Identity Random amplified polymorphic DNA (RAPD) analysis (Technical Note T2) TSOP Adventitious Agents 28 day in vitro assay using 3 cell lines (Technical Note T3) TSOP182 6 Minimum 1e7 cells (plus 30 ml supernatant) In vivo adventitious agent assay: adult and suckling mice and embryonated eggs as outlined in ICH Q5A (Technical Note T4) SP-GSM ml at 1e7 cells /ml Retroviruses (Technical Note T5) Detection of murine xenotropic retroviruses by Mus dunni co-cultivation followed by MiCl S+L- assay TSOP131 6 Live cells required Fluorescent Product Enhanced Reverse Transcriptase TSOP ml cell free supernatant Examination of 200 cell profiles by Transmission Electron Microscopy (TEM) TSOP190 3 Live cells required Species Specific Viruses Hamster Antibody Production Test (HAP), 5 viruses (Technical Note T6) SP-GSM e7 cells/ml in 13 ml spent supernatant Mouse Antibody Production Test (MAP), 16 viruses (Technical Note T7) SP-GSM e7 cells/ml in 13 ml spent supernatant Bovine and Porcine virus screen by real-time PCR (Technical Note T8) TSOP vial containing minimum 5e6 cells Detection of MVM by real-time PCR (Technical Note T9) TSOP vial containing minimum 1e6 cells Detection of Vesivirus by real-time PCR (Technical Note T9) TSOP vial containing minimum 1e6 cells Genetic Analysis Confirmation of sequence of transgene (coding region) by mrna sequencing Design and qualification of a real-time PCR for copy number determination of the transgene TSOP vial containing minimum 1e6 cells TSOP Determination of insert gene copy number by quantitative real time PCR TSOP vial containing minimum 1e6 cells Restriction enzyme analysis by Southern Blot TSOP vial containing minimum 5e6 cells Table 2 MCB and EPC testing 4
5 Working Cell Bank (WCB) Testing The WCB is derived from a vial of the MCB, and may be used as a starting cell substrate for drug production. Less extensive testing is required for the WCB, as the MCB has already been fully characterised, hence a package of limited testing should be performed to confirm identity, ensure that the bank is sterile and demonstrate absence of mycoplasma. In some cases full testing may be performed on the WCB as an alternative to the MCB. An outline of testing required on the WCB is shown in Table 3. Description Microbiological contaminants Sterility test by direct inoculation (Eu Pharm current edition sterility, US Pharmacopeia <71> (Technical Note T1) SP-GSM Test 1% of cell bank (minimum 2 vials) Test for mycoplasma (Eu Pharm, current edition mycoplasmas and USP - NF Mycoplasma test, USP <63> current edition) (Technical Note T1) SP-GSM Test 1 vial + 23 ml supernatant Identity Random amplified polymorphic DNA (RAPD) analysis (Technical Note T2) TSOP Table 3 WCB testing Bulk Harvest (Unprocessed Bulk) Testing A representative of the unprocessed bulk, which consists of pooled harvests of cells and culture media from the fermenter or production reactor, should be analysed for the presence of virus. Data from at least 3 lots of bulk harvest is required for submission to the regulatory authorities. Certain specifics relating to the process, materials and intended product may need to be taken into consideration when determining the bulk harvest testing schedule, however, in general, the following testing regime would be recommended. Description Microbiological contaminants Microbiological examination of non-sterile products: microbial enumeration test (Eu Pharm current edition ) (Bioburden) Test for mycoplasma (Eu Pharm, Current edition mycoplasmas and USP - NF Mycoplasma test, USP <63> current edition ) (Technical Note T1) SP-GSM ml SP-GSM Test 1 vial + 23 ml supernatant Adventitious Agents 14 day in vitro assay using 3 cell lines (EP and FDA compliant) TSOP164 4 Minimum 1e7 cells (plus 30 ml supernatant) In vivo adventitious agent assay: adult and suckling mice and embryonated eggs as outlined in ICH Q5A SP-GSM ml at 1e7 cells /ml Retroviruses Virus detection and quantitation by thin section TEM TSOP e7 cells Species Specific Viruses Detection of MVM by real-time PCR TSOP vial containing minimum 1e6 cells Table 4 Unprocessed Bulk Harvest testing Purified Bulk Harvest and Final Product testing The purified bulk and final product is a sample taken from the end of production process after downstream purification activities have been performed. These samples should be analysed for the presence of viruses. Depending on the manufacturing process, the safety testing of bulk harvests may be conducted on individual batch samples or upon pooled samples from different bulk harvest preparations. Certain specifics relating to the process, materials and intended product may need to be taken into consideration when determining the bulk harvest testing schedule, however, in general, the following testing regime would be recommended. 5
6 Description Microbiological contaminants Sterility test and qualification of sterility test by direct inoculation (Eu Pharm current edition sterility, US Pharmacopoeia <71>) (Technical Note T1) Endotoxin SP-GSM Test 1% of cell bank (minimum 2 vials) plus 3X number tested for qualification Detection of Endotoxin using Chromogenic LAL kit TSOP ml General Safety/Abnormal Toxicity Abnormal Toxicity Test (EU Pharm current edition 2.6.9) SP-GSM No more than 7 human doses Residual Impurities (Bulk Purified Product Only) Detection of residual CHO DNA by real time PCR TSOP ml Determination of CHO Host Cell Proteins (HCP) by ELISA (Technical Note T10) TSOP ml Table 5 Purified Bulk Harvest and Final Product testing Genetic Stability Testing ICH Guidelines indicate that the stability and integrity of the insertion sequence needs to be characterised to ensure stable production of the correct protein. There are a number of steps which are required to be undertaken to ensure the cell line and production system is acceptable. The minimal characterisation required is to assess the MCB and the EPC. Testing can also be carried out at other times but is particularly useful where there are changes to the fermentation process. BioOutsource offers the following genetic stability assays and can advise on the most appropriate approach for your product. Description Confirmation of sequence of transgene (coding region) by mrna sequencing TSOP vial containing minimum 1e6 cells Random amplified polymorphic DNA (RAPD) analysis TSOP Determination of insert gene copy number by quantitative real time PCR TSOP vial containing minimum 1e6 cells Restriction enzyme analysis by Southern Blot TSOP vial containing minimum 5e6 cells Table 5 Genetic Stability Testing Further Possible Testing Qualification and Validation of s `` BioOutsource has extensive experience in the qualification and validation on all assays used to support safety testing of a licenced product. BioOutsource Certification BioOutsource has both GMP and GLP certification; last inspection dates being 27th and 28th July and 16th September 2015 respectively. Following several successful MHRA inspections, BioOutsource were rated with a low risk rating and have continued GMP and GLP compliance and certification; valid until Most recently BioOutsource was successfully audited by the U.S. Food and Drug Administration on 25th and 26th January The inspection confirmed that BioOutsource s Glasgow site, is compliant with the principles and guidelines of GMP. Furthermore, not a single 483 observation for non-compliance was issued. 6
7 Technical notes T1. Qualification of the cell bank sample in the mycoplasma and sterility tests is required once on the MCB and does not need to be repeated on future samples unless there is a change in the materials or manufacturing method. For the sterility test, if antibiotics have been used in cell culture, an alternative membrane filtration sterility test can be performed. T2. Isoenzyme analysis of cell lines is no longer unavailable, due to supply issues. RAPD analysis is available as an alternative to isoenzyme analysis of cell lines. T3. For the MCB, the more sensitive 28 day in vitro assay is recommended. T4. For in vivo tests, various options for inoculation include both the yolk sac and allantoic membrane in eggs, suckling mice, intracranial and intramuscular route in adult mice, as well as the option to include guinea pigs. Animal Volume Required Concentration Yolk sac 6 ml 1 x 10 7 cells/ml Allantoic 6 ml 1 x 10 7 cells/ml Suckling Mice 2 ml 1 x 10 7 cells/ml Adult Mice Intracranial route 1 ml 1 x 10 7 cells/ml Intramuscular route 2 ml 1 x 10 7 cells/ml Guinea Pigs 1.2 ml 1 x 10 7 cells/ml T5. CHO cell lines contain an endogenous, defective, noninfectious retrovirus. When testing for retrovirus, a number of approaches can be taken and it is not necessary to perform all of the procedures. a. The electron microscope is a powerful tool used to visualise retroviral particles (for example budding C-type, R-type and intracisternal A-type particles) b. The PERT assay is used to detect enzymatic activity (which could provide a positive result as hamster cells contain an endogenous, defective, non-infectious retrovirus). c. Cell based in vitro assays for detection will determine if virus detected is infectious. In the event that infectious virus is detected, cells can be co-cultivated with a human cell line to determine if infection of human cells is possible. The PERT test may produce a positive result, and should only be performed following the infectivity and TEM tests. T6. The HAP test will detect the following viruses; Lymphocytic Choriomeningitis virus (LCMV), Pneumonia Virus of Mice (PVM), Reovirus Type 3, Sendai Virus and Simian virus type 5 (SV5). T7. The MAP test will detect the following viruses; Ectromelia Virus; Lymphocytic Choriomeningitis virus, Hantaan Virus, Pneumonia Virus of Mice (PVM), Reovirus Type 3, Mouse Theilers Encephalomyelitis Virus, Lactic Dehydrogenase Virus, Sendai Virus, Minute Virus of Mice (MVM), Mouse Adenovirus, Mouse Cytomegalovirus, Mouse Hepatitis Virus, Mouse Rotavirus, Polyoma Virus, Thymic Virus and K virus. T8. If at any point during production, cells have come into contact with bovine serum or porcine trypsin full testing for a range of bovine and porcine viruses should be performed. Bovine Polyomavirus, in particular, has been requested by the European regulators, as it has been found as a frequent contaminant of foetal bovine serum. T9. It is recommended that testing for the presence of Minute Virus of Mice (MVM) should be performed on production harvests and the EPC. This virus has previously been detected as a contaminant in CHO fermentations, and testing for its presence can be performed by inclusion of an additional cell line susceptible to MMV infection in the in vitro assay, for example 324K cells, or alternatively by performing a real time PCR assay. Similarly vesivirus has also been detected in biological materials used in product manufacture. T10. A validated HCP assay is required for the final product testing of licenced biologics. The assay listed here is a screening assay for early phase clinical material. Further discussion will be required if BioOutsource is to develop a specific HCP assay for late phase material. Please contact BioOutsource for further information regarding this. s 1. ICH Q5A (R1) Viral Safety Evaluation of Biotechnology products derived from cell lines of human or animal origin. 7
8 Sartorius Stedim BioOutsource Global Facilities For further contacts, visit Glasgow, UK Laupheim, Germany Pangyo, South Korea Glasgow 1 Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, United Kingdom Phone Fax Laupheim Sartorius Stedim Cellca Erwin-Rentschler-Str Laupheim, Germany Phone: Fax: Follow Us Pangyo 8th Floor, Solid Space B/D, PanGyoYeok-Ro 220, BunDang-Gu SeongNam-Si, GyeongGi-Do, South Korea Phone Fax Specifications subject to change without notice. Printed in the EU on paper bleached without chlorine. Publication No.: S e Order No.: Ver
Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products
Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products Founded in 96, Eurofins Lancaster Laboratories is a global leader in comprehensive laboratory services enabling
More informationBiosafety Considerations for Cell Based Viral Vaccines. Margaret Temple SGS Vitrology Site Director Glasgow - UK
Biosafety Considerations for Cell Based Viral Vaccines Margaret Temple SGS Vitrology Site Director Glasgow - UK Presentation Outline: Sources of adventitious contamination in biological material Safety
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationEuropean Guideline for Virus Safety Evaluation of Clinical Trial Material
Plasma Product Biotechnology Meeting, May 8 12, 2007 European Guideline for Virus Safety Evaluation of Clinical Trial Material Dr. Hannelore Willkommen Vice President Regulatory Affairs, NewLab Bioquality
More informationEuropean Medicines Agency
European Medicines Agency October 1997 CPMP/ICH/295/95 ICH Topic Q 5 A (R1) Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal
More informationCritical Quality Attributes for Live Viral Vaccines. Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA
Critical Quality Attributes for Live Viral Vaccines Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA Terminology Quality Release Standards The specifications and procedures
More informationFast decisions instead of delays Quality Control through outstanding design
Fast decisions instead of delays Quality Control through outstanding design We are CustomBiotech from Roche In your operations, behind your decisions, powering your products You are driving a paradigm
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationGuidance for FDA Review Staff and Sponsors
Guidance for FDA Review Staff and Sponsors Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) DRAFT GUIDANCE
More informationOutsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D.
Outsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D. Should You Partner Manufacturing? $$$ versus Control 2 Ph. 1 Registration Trials Commercial Launch CMO CMO or Partner CMO
More informationAnnex 4. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology
Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology Replacement of Annex 3 of WHO Technical Report Series, No. 814 Introduction 177
More informationProduct Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex
Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Brand Name : BOTO GENIE 1. Introduction : BOTO GENIE (Botulinum Toxin Type A for Injection Ph.Eur)
More informationGuidance for Industry
Guidance for Industry Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious
More informationReference Materials for Adeno-Associated Viruses
Reference Materials for Adeno-Associated Viruses : Recommendations of the Quality Control Sub-Committee John Chiorini (NIH-NIDCR) Paul Husak (Cell Genesys) Gabrielle Kroener-Lux (Progen) James Marich (Cell
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationSmall Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre
Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre Keith Williams Business Development Manager - Clinical Biotechnology Centre CBC - Aims and Objectives
More informationNational Institute of Immunology, New Delhi
National Institute of Immunology, New Delhi QUOTATION INVITATION NOTICE For Website Ref: NII/AKS/GPL/2013 Date: 25/12/2013 Quotations are invited from technical firms specializing in either both or one
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES
More informationViral Clearance Services. Unsurpassed experience, science and compliance
Viral Clearance Services Unsurpassed experience, science and compliance What We Do BioReliance has conducted thousands of Clearance studies for clients around the globe. These studies are required by regulatory
More informationRegulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products
Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT
More informationGuideline on quality of biological active substances produced by transgene expression in animals
1 2 3 24 May 2012 EMA/CHMP/BWP/159188/2012 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on quality of biological active substances produced by transgene expression Draft Draft
More informationCQAs for C> Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline
CQAs for C> Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development
More informationMONOCLONAL ANTIBODIES AND BIOSIMILARS production, naming, pharmacovigilance and other pharmaceutical quality aspects
1 MONOCLONAL ANTIBODIES AND BIOSIMILARS production, naming, pharmacovigilance and other pharmaceutical quality aspects Prof. dr. Jos G.W. Kosterink Department of Clinical Pharmacy and Pharmacology University
More informationRegulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank
Regulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank Rashmi Rawat, Ph.D. Office of Biotechnology Products OPQ/CDER/FDA Informa Life Sciences Annual Cell Line Development
More informationAccredited Laboratory
Accredited Laboratory A2LA has accredited St. Paul, MN for technical competence in the field of Biological Testing This laboratory is accredited in accordance with the recognized International Standard
More informationDownscaling Purification Processes for Biologics
Clearance Services Considerations in Downscaling Purification Processes for Biologics O-0280608 About BioReliance BioReliance Corporation is a leading provider of cost-effective contract services to the
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationJ. Fraser Wright, Ph.D.
Towards Better Characterization of Recombinant AAV Gene Transfer Vectors: Case Studies Illustrating Challenges with Dose Determining Vector Concentration methods J. Fraser Wright, Ph.D. Well Characterized
More informationGala s Gene Product Expression (GPEx ) Platform
Gala Biotech A Company with Gene Insertion and Manufacturing Technologies for the Next Generation of Gene Expression and Biologics Production Gala s Gene Product Expression (GPEx ) Platform Rapid creation
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationHow can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines?
How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines? Marion F. Gruber, Ph.D. Office of Vaccines Research and Review CBER/FDA Global Vaccine
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationEuropean Directorate for the Quality of Medicines & HealthCare (EDQM)
European Directorate for the Quality of Medicines & HealthCare (EDQM) INTERNATIONAL REGULATORY FORUM OF HUMAN CELL THERAPY AND GENE THERAPY PRODUCTS 16 MARCH 2016, OSAKA, JAPAN Dr Stephen J. Wicks Scientific
More informationManufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of
More informationGuideline on requirements for the production and control of immunological veterinary medicinal products
14 June 2012 EMA/CVMP/IWP/206555/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on requirements for the production and control of immunological veterinary Draft agreed by Immunologicals
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationEuropean Regulatory Experiences and Expectations of HCP Analysis and Control
HCP Strategy Forum, Washington DC, January 26, 2015 www.pei.de European Regulatory Experiences and Expectations of HCP Analysis and Control Blood Products: Dr. Erika Friedl, PEI (DE) Discalimer: The views
More informationRapid Microbiological Methods Understanding the Technologies and Regulatory Expectations for Validation and Implementation
Rapid Microbiological Methods Understanding the Technologies and Regulatory Expectations for Validation and Implementation Michael J. Miller, Ph.D. President Microbiology: Where We ve Been 1683. Anton
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationTechnical Report No. 71 Emerging Methods for Virus Detection
Technical Report No. 71 Emerging Methods for Virus Detection PDA Emerging Methods for Virus Detection Technical Report Team Authors Arifa S. Khan, Ph.D., U.S. FDA/CBER, Co-Leader Kathryn E. King, Ph.D.,
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationJapanese Application Form: PMDA s Perspective on Manufacturing Process Description
Japanese Application Form: PMDA s Perspective on Manufacturing Process Description Reiko YANAGIHARA, Ph.D. Principal Reviewer Division of Pharmacopoeia and Standards for Drugs Office of Standards and Guideline
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationQuestions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility
15 June 2017 EMA/CVMP/ADVENT/751229/2016 Committee for Medicinal Products for Veterinary Use (CVMP) Questions and Answers on allogenic stem cell-based products for veterinary use: Draft problem statement
More informationCase Study: Examples Relating to the Quality Control of Cell-based Products
Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX BATCH Q: Quality Q1A(R2) Stability Testing of New Drug Substances
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Guidelines on procedures and data requirements for changes to approved biotherapeutic products World Health Organization
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationA Regulatory Perspective on Characterization and Control of Process-Related Impurities
A Regulatory Perspective on Characterization and Control of Process-Related Impurities Christopher Downey, PhD FDA/CDER Office of Biotechnology Products CASSS Bay Area Discussion Group June 2017 Disclaimer
More informationICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada
ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada Anthony Ridgway, Ph.D. Senior Regulatory Scientist Biologics & Genetic Therapies Directorate Health Canada Open
More informationRegulatory Implications for Global Manufacturing Development of Regenerative Medicines
Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells
More informationRecombinant DNA Technology. The Role of Recombinant DNA Technology in Biotechnology. yeast. Biotechnology. Recombinant DNA technology.
PowerPoint Lecture Presentations prepared by Mindy Miller-Kittrell, North Carolina State University C H A P T E R 8 Recombinant DNA Technology The Role of Recombinant DNA Technology in Biotechnology Biotechnology?
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationPreclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015
Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle
More informationLentiviral Vector Manufacturing Challenges and Solutions
Lentiviral Vector Manufacturing Challenges and Solutions Bo Kara Cell Gene Therapy CMC Elizabeth and Patience Save the Children clinic attendee Liberia Photo credit Martin Web/Save the Children Strategy:
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines
0 0 0 0 WHO/PAC for BTPs_DRAFT/ Oct 0 ENGLISH ONLY Guidelines on procedures and data requirements for changes to approved biotherapeutic products Proposed guidelines NOTE: This document has been prepared
More informationSubmission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014)
31 August 2015 Submission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014) Comments from: Name of organisation or
More informationExcipient Albumin CSL Behring Human Serum Albumin
Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse
More informationChapter 9 Genetic Engineering
Chapter 9 Genetic Engineering Biotechnology: use of microbes to make a protein product Recombinant DNA Technology: Insertion or modification of genes to produce desired proteins Genetic engineering: manipulation
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationFRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and
More informationViraBind PLUS Retrovirus Concentration and Purification Kit
Product Manual ViraBind PLUS Retrovirus Concentration and Purification Kit Catalog Number VPK-135 2 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Retroviral gene transfer
More informationQualified Persons in the Pharmaceutical Industry Study Guide
Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013
More informationArchived Content. This content was archived on June 24, 2013.
This content was archived on June 24, 2013. Archived Content Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after
More informationTurboFect in vitro Transfection Reagent. Description. Storage. Reagents to be Supplied by the User. #R ml ( for in vitro transfections)
TurboFect in vitro Transfection Reagent #R0531 1 ml ( for 300-500 in vitro transfections) Description TurboFect in vitro Transfection Reagent* is a sterile solution of a cationic polymer in water. The
More informationPARTIALLY PURIFIED LENTINAN FROM SHIITAKE MUSHROOM (LENTINUS EDODES) STILL RETAIN ANTITUMOUR ACTIVITY
-------The 3 rd ICMBMP October 1999 PARTIALLY PURIFIED LENTINAN FROM SHIITAKE MUSHROOM (LENTINUS EDODES) STILL RETAIN ANTITUMOUR ACTIVITY Ann-Teck Yap, Sudhir Kumar Chandramohan, Mah-Lee Ng Mary Department
More informationABL Europe s GMP manufacturing facility for viral vector production
ABL Europe s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors Success Story ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures
More informationThe Chairperson of Korea Association for IACUC The Chairperson of SNU IACUC The Chairperson of National Animal Welfare Committee Laboratory Animal
The Chairperson of Korea Association for IACUC The Chairperson of SNU IACUC The Chairperson of National Animal Welfare Committee Laboratory Animal Medicine, College of Vet Med, SNU Prof. Jae Hak PARK 1.
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationCHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Cells for Biopharmaceutical Production Bacteria and Yeasts Systems Animal Cell Systems Insect
CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Cells for Biopharmaceutical Production Bacteria and Yeasts Systems Animal Cell Systems Insect Cell Systems Cell Lines and Cell Banks Fermentors and
More informationCell History File Explanatory Introduction
CELL HISTORY FILE TEMPLATE Cell History File Explanatory Introduction This template Cell History File (CHF) is a non-mandatory template document intended for establishments and companies involved in the
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationViraBind PLUS Retrovirus Concentration and Purification Mega Kit
Product Manual ViraBind PLUS Retrovirus Concentration and Purification Mega Kit Catalog Number VPK-136 VPK-136-5 2 preps 10 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction
More informationUtility of a Recombinant Adeno-Associated Viral Vector Reference Standard BY Terence R. Flotte, Parris Burd, and Richard O. Snyder
Utility of a Recombinant Adeno-Associated Viral Vector Reference Standard BY Terence R. Flotte, Parris Burd, and Richard O. Snyder Recombinant Adeno-associated viral (raav) vectors are known to be efficient
More informationVaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study.
Vaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study. CMC Forum Vienna May 25-27 Vaccine workshop M.-C. Uwamwezi, Senior scientist Regulatory Affairs,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationUSP Standards for Ancillary Materials
Quality Standards for Medicines, Supplements, and Food Ingredients throughout the World USP Standards for Ancillary Materials 8 th Annual Somatic Cell Therapy Symposium September 22-24 2008 Fouad Atouf,
More informationBSA FRACTION V BOVINE SERUM ALBUMIN
BSA FRACTION V BOVINE SERUM ALBUMIN BOVINE SERUM ALBUMIN PROLIANT BSA Proliant is the world s largest and most experienced manufacturer of animal-derived proteins, producing a variety of grades of Fraction
More informationIntroducing new DNA into the genome requires cloning the donor sequence, delivery of the cloned DNA into the cell, and integration into the genome.
Key Terms Chapter 32: Genetic Engineering Cloning describes propagation of a DNA sequence by incorporating it into a hybrid construct that can be replicated in a host cell. A cloning vector is a plasmid
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
Ref. Ares(2012)778531-28/06/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health Systems and Products Medicinal Products - Quality, safety and efficacy Brussels, SANCO/AM/sl/ddg1.d.6(2012)860362
More information[DOCKET NO. 96N-0400] Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications
[DOCKET NO. 96N-0400] Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications For further information about this document, contact: Valerie A. Butler Center for Biologics
More informationOptimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk. Feng Gao, MD, PhD. AutekBio CO.
Optimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk Feng Gao, MD, PhD AutekBio CO. Expression Systems used for Approved Antibody and Antibody-Related
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationPRINCIPLES OF VETERINARY VACCINE PRODUCTION
NB: Version adopted by the World Assembly of Delegates of the OIE in May 2008 CHAPTER 1.1.6. PRINCIPLES OF VETERINARY VACCINE PRODUCTION SUMMARY A reliable supply of pure, safe, potent, and effective vaccines
More informationExecutive Summary. clinical supply services
clinical supply services case study Development and NDA-level validation of quantitative polymerase chain reaction (qpcr) procedure for detection and quantification of residual E.coli genomic DNA Executive
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationCREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO
CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO STATE-OF-THE-ART GMP FACILITIES Our sites in Jena and Halle (Germany) provide a complete range
More informationContent of the dossier for chemical purity and microbiological quality
Division Certification of Substances CP/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/ CEP (0) 1 R February 0 Certification of suitability of Monographs of the European Pharmacopoeia
More informationCAS INTRO is pages
CAS INTRO is 6.33-6.50 pages V I R U S S A F E T Y OVERVIEW Methodologies for Viral Safety by Cheryl Scott Good manufacturing practices (GMPs), as agreed upon by the World Health Organization and regulatory
More informationComparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm
Comparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm Jarrod Dean Principal Research Associate, Analytical Development Sanofi Presented by GTC, a
More informationA Unique LC-MS Assay for Host Cell Proteins(HCPs) ) in Biologics
A Unique LC-MS Assay for Host Cell Proteins(HCPs) ) in Biologics Catalin Doneanu,, Ph.D. Biopharmaceutical Sciences, Waters September 16, 2009 Mass Spec 2009 2009 Waters Corporation Host Cell Proteins
More information